Histamine release after intravenous application of short-acting hypnotics. A comparison of etomidate, Althesin (CT1341) and propanidid by Doenicke, A. et al.
Brit. J. Anaesth. (1973), 45, 1097
HISTAMINE RELEASE AFTER INTRAVENOUS APPLICATION OF
SHORT-ACTING HYPNOTICS
A Comparison of Etomidate, Althesin (CT1341) and Propanidid*
A. DOENICKE, W. LORENZ, R. BEIGL, H. BEZECHY, G. UHLIG, L. KALMAR,
B. PRAETORIUS AND G. MANN
SUMMARY
The subject of histamine release was investigated in 16 volunteers by means of plasma
histamine determination after the administration of etomidate, Althesin, propanidid, and
Cremophor EL. Althesin and propanidid caused release of histamine in various degrees
of frequency. Blood pressure changes were rather pronounced with both anaesthetic
agents; tachycardia reached its mavimiim in the first and second minute, which seems
to be an argument against histaminp release as the underlying cause of this reaction.
Histamine was, indeed, only released to such an extent (with the exception of one
borderline case) that no clinical symptoms other than secretion of gastric juice and
erythema were to be expected. After the application of etomidate and Cremophor EL
an increase in plasma histamine was not detectable. Changes in the differential Wood
picture in terms of a decrease in basophils only occurred after Althesin and propanidid;
not, however, after etomidate and Cremophor EL. Etomidate is, therefore, the first
hypnotic drug for intravenous application which is unlikely to cause chemical histaminp
release.
The increasing incidence of anaphylactic and anaphy-
lactoid reactions after the administration of anaes-
thetic agents, muscle relaxants and plasma substi-
tutes in recent years has enhanced the clinicians'
interest in the question of drug-induced histamine
release. After experiments in man and animals,
certain circulatory reactions of unknown origin
resulting from the administration of short-acting
intravenous anaesthetics can now be explained by
the release of pharmacologically highly potent hista-
mine (Doenicke and Lorenz, 1970; Lorenz et al.,
1969, 1970, 1971, 1972a,b,d; Seidel et al., 1973).
Our team (Lorenz et al., 1972b) has pointed out
repeatedly that the circulatory effects of anaesthetic
agents must be carefully analysed before physical or
biochemical mechanisms can be held responsible for
the clinical manifestations of certain signs and symp-
toms. Various studies (Kettler et al., 1970; Patschke
et al., 1972; Soga and Beer, 1972; Sonntag et al.,
1973) seem to indicate that the fall in arterial pres-
sure frequently observed during the first 3 minutes
after injection of the anaesthetic is caused by, among
other mechanisms, reduced myocardial contractility.
The delayed decrease in blood pressure after
propanidid, however, often accompanied by allergic
skin reactions, depends on a massive histamine
release into the circulatory system (max. about 5
minutes after the injection) (Lorenz et al., 1972b).
Two new short-acting anaesthetics (hypnotics) are
under clinical investigation at present, i.e. etomidate
and Althesin (CT1341) and the question arises as to
whether they can release histamine under certain
conditions. These studies with volunteers were pre-
ceded by clinical experiments carried out by various
groups (Benke et al., 1972; Campbell, 1972; Camp-
bell et al., 1971; Clarke et al., 1971; Hempelmann
et al., 1973) with Althesin, and by our team (Doenicke
and Kugler, 1973, unpublished; Doenicke et al.,
1973a; Doenicke, Wagner and Beetz, 1973b) with
etomidate. The experience dius acquired justifies a
clinical-experimental study in man, since etomidate,
in particular, proved to be a hypnotic devoid of ad-
verse circulatory effects.
In the first study on etomidate, Janssen and associ-
ates (1971) reported on its hypnotic and toxic effects
in rats when it was given in increasing concentra-
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tions. It was concluded from such comparative
animal trials that etomidate, because of its relatively
large safety margin, appeared to be excellent as com-
pared with the other hypnotics, its LD J0 being 30
times that of the hypnotic dose. We therefore con-
sidered it reasonable to assess the action of etomidate
in man, whilst observing the necessary precautionary
measures.
Etomidate is a carboxylate, such as is carbamoyl
propylester (propanidid), and is injected intraven-
ously. From the similarity of both substances one
would expect a short narcotic action and rapid break-
down of etomidate since, as with propanidid, enzy-
matic hydrolysis in serum and liver is supposed to
occur.
MATERIAL AND METHODS
Material
Drugs.
Etomidate (Janssen Pharmaceutics, Belgium) is R-l-
ethyl-l-(a-inethyl-benzyl) imidazole-5-carboxylate, avail-
able as an aqueous solution and neutralized with phosphate
buffer (Janssen et al., 1971) (fig. 1).
-H
FIG. 1. Structural formula of etomidate.
Althesin (CT1341) (Glaxo, England) is composed of
two steroids: 0.9% 3a-hydroxy-5a-pregnane-ll, 20 dione,
and 0.3% 21-acetoxy-3a-hydroxy-5a-pregnane-ll, 20 dione.
These two components, both slightly soluble in water,
are dispersed with 20% Cremophor EL, 0.25% sodium
chloride, and water, with the object of obtaining an
injectable mixture (fig. 2).
OH
FIG. 2. Structural formula of the steroids contained in
Althesin (CT1341).
Epontol (Bayer, Leverkusen) is a colloidal solution
consisting of propanidid (3 - methoxy - 4(N, N - diethyl -
carbamoylmethozy) pfaenyl - acetic add - n - propyl -
ester, Micellophor (20%), various salts, and water (Scholtan
and Sue Yung Lie, 1966).
Cremophor EL (BASF, Ludwigshafen) contains 84%
of hydrophobic ORPE (oleum ricini polyoxyethylate
Elbersfeld) and 16% of a hydrophilic mixture of poly-
glycols and glycerine-polyglycol-ethers—atropinum sul-
furicum (medicinal).
Reagents.
Histamine dihydrochloride o-phthaldialdehyde (Fluka,
Buchs), Dowex 50 W-X8, H+ (Serva, Heidelberg)—
organic and inorganic solvents as Uvasol (Merck, Darm-
stadt). For purity and detailed specification of the reagents
see Lorenz et al. (1972c).
Anaesthesia and Trial Scheme
Anaesthesia, trial scheme and measuring methods have
already been described in detail in a previous publication
(Lorenz et al., 1972a).
The trial group comprised 16 male, anamnestically
healthy volunteers, between 21 and 33 years of age and
weighing 58-85 kg. They had been fasting for at least 6
hours.
Trial procedure.
Anaesthesia was carried out with spontaneous breathing
between 8 a.m. and 4 pjn. over several days. Fifteen
minutes before injecting the anaesthetic agent, a catheter
(Braunula) was placed in a forearm vein, two blood
samples were taken for plasma histamine determination
and blood count purposes, and an intravenous injection
of atropine 0.5 mg was given. The rates of injection
were: 20 sec for etomidate 0.2 mg/kg bw and
propanidid 5 mg/kg bw, 60 sec for Althesin 0.075 ml/kg
bw, and 10 sec for Cremophor EL 0.15 ml/kg bw. The
other arm was used for measurement of blood pressure.
Measuring Methods
Plasma histamine determination.
Plasma was obtained, using the method of Lorenz and
associates (1972c); 19.5 ml whole blood was taken from each
of the volunteers immediately before anaesthesia and 1, 5,
10, 20 and 30 min after injecting the anaesthetic agent.
Histamine was isolated by ion exchange chromatography
with Dowex 50 W-X8 and subsequent extraction into
alkaline butanol and was determined fluorometrically after
condensation with 0.05% cr-phthaldialdehyde.
The blood pressure was measured at 1-min intervals
by auscultation using the Riya Rocci technique; the heart
rate was continuously monitored by electrocardiogram
(Hellige Multiscriptor EK22) up to 20 min after injecting
the anaesthetic agent.
The differential blood count was determined from
venous blood by counting 1,000 cells from each of two
samples, using Pappenheim staining. Total white blood
cells per mrr? were counted by means of a counting
chamber. For details of the method of counting basophils
and eosinophils, see Lorenz and associates (1972c).
Evaluation.
Results were statistically evaluated by means of the
Student r-test.
RESULTS
Plasma histamine concentrations.
After intravenous injection of anaesthetic agents
(hypnotics) and plasma substitutes in man and dog,
release of histamine is not invariable, but occurs
only in a certain number of test persons or animals.
The occurrence of an increase in plasma histamine
levels or even of serious anaphylactic incidents varies,
and with high-molecular mixtures (Cremophor EL
and Micellophor in our case) it even varies from
batch to batch. It is, therefore, not surprising that
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in comparison with previous investigations (Lorcnz
et al., 1972a,b) the release of histamine following the
administration of Epontol (active substance propani-
did+Micellophor) occurred comparatively infre-
quently (fig. 3c), which is probably attributable to
die dosage reduction from 7 to 5 mg/kg body weight.
If, however, the same subjects who had received
propanidid, were treated with etomidate (the
sequence of administration of the two drugs being
randomized with the aid of random tables), none of
the 8 volunteers showed evidence of histaminp release
(fig. 3A). The plasma histamine level rose after
Althesin in 4 of 8 volunteers (fig. 3B). The course of
this reaction corresponds to that obtained with pro-
panidid and thiopentone, as we had been able to
demonstrate already (Doenicke and Lorenz 1970;
Lorenz et al., 1972b). Since methohexitone also causes
histamine release corresponding to that caused by
the other anaesthetics mentioned (Seidel et al., 1973),
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etomidate is the only short-acting anaesthetic
(hypnotic) for intravenous application so far tested
which is not associated with a detectable degree of
histamine release.
The increase in plasma histamine levels found in
the volunteers has no direct clinical significance
(Doenicke and Lorenz, 1970; Lorenz et al., 1972b).
It indicates, however, that massive nistnminr release
might occur under unfavourable conditions with the
possible risk of life-threatening anaphylactoid incid-
ents (Doenicke and Lorenz, 1970; Lorenz et al.,
1972b). Furthermore, the possibility of the anaes-
thetically-induced histamine release being at least
partly responsible for the postoperative occurrence
of stress ulcers cannot be excluded (Seidel et al.,
1973).
The same volunteers, who were treated with
Althesin, also received the solvent Cremophor EL in
the same type of injection mixture as used in the
-10 O 20 30
Time [mini
FIG. 3B
FIG. 3. Plasma histamine concentrations in volunteers
after intravenous administration of etomidate, Althesin
and propanidid. Mean values ± SEM.
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preparation of Althesin. In none was an increase in
plasma histamine levels found; these had been within
normal limits before the injection.
In one volunteer (Hal.) the plasma hisraminp con-
centration rose to 3.8 ng/ml, remained at the 3.5
ng/ml level for 10 min and fell to 0.8 ng/ml only
at the 30th min, thereby approaching the initial
value (fig. 4).
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FIG. 4. Plasma histamine concentrations, basophilic con-
tent of venous blood, heart rate, and arterial blood
pressure of volunteer Hal. after injecting Althesin.
The basophilic granulocytes decreased by 60%,
which was not compensated after 30 min. Blood
pressure values dropped temporarily by about 25 mm
Hg, which cannot be attributed to histamine release.
A prolonged mild tachycardia was observed, how-
ever, for which histamine as a partially causative
factor may not be excluded. The same volunteer
showed no significant changes in haemogram, blood
pressure, and heart rate after Cremophor, which was
administered 14 days after anaesthesia with Althesin.
With regard to histamine release, the volunteer
(Hal.) is already to be considered a borderline case,
who, after another dose of Althesin accompanied by
unfavourable conditions (Lorenz et al., 1972b),
might develop a more severe reaction with corre-
sponding clinical symptoms and signs.
Blood pressure and heart rate.
After the administration of Althesin a significant
hypotension occurred, averaging 15% compared with
preanaesthetic values (fig. 5B) (see Patschke et al.,
1972, and Benke et al., 1972). A mild degree of
tachycardia was observed, reaching its maximum in
the second minute and lasting distinctly longer than
had been the case with thiopentone and propanidid
(Lorenz et al., 1972b).
By comparison, the circulation after the adminis-
tration of etomidate showed a marked stability in all
volunteers. Systolic and diastolic blood pressures
showed only very small changes and the heart rate
only rose from 70 to 95 beats/min in the first minute
following the injection (fig. 5A). This rise was of
statistical significance.
The same volunteers exhibited a significant
decrease in blood pressure (P<0.05) at the first and
second minutes after propanidid, the systolic pres-
sure being more affected than the diastolic (fig. 5c).
At the same time marked tachycardia was noted with
the heart rate rising by an average of 60% during
the first and second minutes (P<0.005). After 5 min,
however, these parameters had more or less regained
initial values.
Injection of Cremophor EL alone had no signi-
ficant effect on the Wood pressures and heart rates
of those volunteers who had already been given
Althesin (fig. 5D), as has already been pointed out
elsewhere (Lorenz et al., 1972a,b).
Total white blood cells, basophilic and eosincrphilic
granulocytes.
After the administration of Althesin the four
volunteers in whom a pronounced increase in plasma
histamine levels had occurred, showed a considerable
decrease in basophils which fell from 56 to 32 cells/
mm1 by the 15th minute, still remaining at this level
after 30 min. The eosinophilic granulocyte counts
also fell in these subjects (fig. 6A).
Four other volunteers, however, exhibited no
change in the blood picture; even after the adminis-
tration of Cremophor EL such a rapid shift of leuco-
cytes was not observed (fig. 6B).
After injection of etomidate the Hood picture
remained unchanged. A fall in basophil coun
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FIG. 5. Arterial blood pressure and heart rate after etomidate, Althesin, propanidid, and
Cremophor EL. (Mean values ±SEM.)
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FIG. 6. Total white blood cells, basophilic and eosinophilic granulocytes in the venous blood
of volunteers after intravenous injection of Althesin and Cremophor EL. (Mean values.)
# # 4 subjects with an increase in plasma histamine levels.
O O 4 subjects with no increase in plasma histamine levels.
could not be detected, whereas after propanidid
injection the basophilic granulocyte count was
reduced but not the eosinophilic. The latter even
increased in number, as we have already reported
(Lorenz et al., 1972b).
Whether there is a causal connection between the
changes in the blood picture and the histamine
release is not certain, but this possibility should not
be excluded, however, considering the reaction of
the basophilic granulocytes. In view of these changes,
histamine determinations in whole blood cannot be
used to demonstrate histaminr release.
Clinical side-effects.
Apart from the circulatory changes described we
noted the clinical side-effects listed in table I after
administration of the drugs under review.
The muscular movements appearing after etomi-
date in 50% of all cases could be called "myocloni"
and are reported in detail elsewhere (Doenicke et al.,
1973a). We were able to largely eliminate these
"myodoni" by injection of diazepam 1 mg/10 kg
in clinico-phannacological experiments with volun-
teers and also in hospital. Muscular movements were
also observed after Althesin, but less frequently after
propanidid.
The development of erythema in the upper half
of the trunk was noted in particular after propanidid
and Althesin, and in one case also after Cremophor
EL. Erythema never occurred, however, after etomi-
date. Histamine release may be responsible for these
erydiemas.
Hyperventilation was always observed after pro-
panidid injection, with or without the subsequent
development of apnoea, and in 4 cases after Althesin.
It did not occur, however, after etomidate. Regard-
 h
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TABLE I. Clinical side-effects after intravenous administration of etomidate, Allhesin, propanidid
and Cremophor EL.
Date (1972):
Etomidate
May 9-13
Althesin
July 3-5
Propanidid
July 3-5
Cremophor EL
July 10-18
Number of volunteers
Muscular movements
Reddening (neck, face, chest)
Hyperventilation
Hyperventilation + apnoea
8
4
0
0
0
8
4
3
2
2
8
1
4
8
1
8
0
1
0
0
ing the absence of clinical side-effects, etomidate,
therefore, appears to be superior to the other sub-
stances examined. For a final and conclusive answer
to this question, controlled studies with randomiza-
tion will be required.
DISCUSSION
In the course of our investigations carried out during
the past six years on histamine release after the
administration of anaesthetic agents and plasma sub-
stitutes, we examined two new non-barbiturate
anaesthetics (hypnotics) in 1972, which have not
yet been marketed in Germany.
By determining three parameters (plasma histamine
level, blood pressure and heart rate) we were able
to demonstrate that propanidid, Althesin, as well as
thiopentone and methohexitone, probably cause a
chemical hisraminf release. This means that hista-
mine may be released from mast cells directly by the
drug and not via an immunological mechanism.
Histamine release after Althesin has not been men-
tioned directly in the literature available so far
(Campbell, 1972; Clarke et al., 1971), but Hempel-
mann and associates (1973), on the strength of
clinical observations, recently suggested the possi-
bility of "allergic reactions".
On the basis of existing experimental investiga-
tions and of our own clinical observations in 2,500
cases we may assume that etomidate is the first
intravenous hypnotic that does not cause release of
histamine. Such a statement should be accepted
with caution, however, from a prognostic point of
view, because sensitization after repeated applica-
tion or the release of histamine under certain condi-
tions (e.g. activation of the complement system) can-
not yet be excluded.
We reported in detail on the clinical symptoms of
histamine release some time ago (Doenicke and
Lorenz, 1970; Lorenz et aL, 1972b). In the case of
propanidid we could again observe erythema and
also signs of urticaria in the face, neck and chest in
60% of the volunteers, but also after Althesin these
symptoms were noticed in 40% of the cases.
We also dealt in detail with the treatment of
anaphylactic shock, should such an incident occur
(Doenicke and Lorenz, 1970; Lorenz et al., 1972b).
In the present study, however, there was no case of a
serious or life-threatening anaphylactoid reaction.
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HISTAMINFREISETZUNG NACH
INTRAVENOSER VERABREICHUNG
KURZWIRKENDER NARKOTIKA: EIN
VERGLEICH ZWISCHEN ETOMIDATE,
ALTHESIN CT1341 UND PROPANIDID
ZUSAMMBNFASSUNG
An 16 freiwiUigen Probanden wurde die Frage einer
Histaminfreisetzung durch Plasma-Histaminbestimmung
nach Etomidate, Aldiesin CT1341, Propanidid und
Crcmophor EL untersucht. Sowohl Althesin CT1341,
als auch Propanidid setzten in verschiedener Haufigkeit
Histamin freL Blutdruckveranderungen waren bei beiden
Narkotika stark ausgepragt, die Tachykardie erreichte
jeweils in der 1. und 2. Minute ihr Maximum, was gegen
eine Histaminfreisetzung als Ursache dieser Reaktion
spricht. Die Histaminfreisetzung war in der Tat nur so
stark (mit Ausnahme eines Grenzfalles), dafi keine
klinischen Symptome mit Ausnahme von Magensaft-
sekretion. und Erythem erwartet werden konnte. Nach
Etomidate und Cremophor EL war ein Histaminanstieg
im Plasma nicht nachweisbar. VerSnderungen im
Differentialblutbild im Sinne eines Abfalles der Basophilen
waren nur nach Althesin CT1341 und Propanidid, nicht
aber nach Etomidate und Cremophor vorhanden. Etomi-
date ist damit das erste i.v. Hypnotikum, bei dessen
Anwendun^ eine chemische Histaminfreiserzung unwahr-
scheinlich isL
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